Usage Examples
- The approval letter carried one PMR for the pediatric safety study and three PMCs covering drug-drug interaction, renal impairment and long-term immunogenicity.
- Our annual report is due in 40 days and two PMCs are still sitting at pending with no protocol finalized.
- Move that PMC to delayed and write the explanation now; do not let the annual report say ongoing when the schedule has already slipped.
What is Post-Marketing Commitment (PMC)?
Post-marketing commitments are studies or clinical trials a sponsor agrees in writing to conduct after FDA approval, not compelled by statute or regulation the way post-marketing requirements are, yet still reported annually until FDA agrees they are fulfilled.
Post-marketing commitments exist because an approval decision is made on data that stops at the trial boundary. FDA is routinely left with residual questions: a subpopulation nobody studied, an interaction nobody characterized, a durability signal nobody followed long enough. When the question does not justify compelling a study, the sponsor offers one instead, in writing, and FDA accepts.
Post-marketing commitments cover studies and clinical trials in clinical safety, clinical efficacy, clinical pharmacology and nonclinical toxicology that the applicant committed in writing to conduct. The boundary is who created the obligation, not what the study measures: the identical protocol is a post-marketing requirement when FDA requires it. Both appear in the same annual status report; only one carries statutory compulsion.
Post-marketing commitments are managed through the annual report cycle rather than as one-off deliverables. Each commitment carries a status of pending, ongoing, delayed, terminated or submitted, filed within 60 days of the anniversary of U.S. approval, with an explanation for any slippage. Reporting does not stop when the final study report goes in; it continues until FDA writes back concurring the commitment is fulfilled.
Not to be confused with
- Post-Marketing Requirement (PMR)
- a PMR is a study FDA required; a PMC is one the applicant offered and FDA accepted. Same annual report, same five status categories, different consequence when the date slips.
- Post-marketing surveillance
- surveillance is the continuous intake of spontaneous safety reports on a marketed product. A PMC is a discrete study with a protocol, a completion schedule and a final study report that closes it out.
- Annual report
- the annual report is the vehicle, the PMC is one of its required contents. 21 CFR 314.81(b)(2)(vii) makes commitment status a mandatory section of that filing, which is why a missed PMC update is an annual-report deficiency, not just a study delay.
- Phase 4 study
- Phase 4 describes when a study runs, after approval. PMC and PMR describe who created the obligation. A Phase 4 study can be a PMC, a PMR, or a purely commercial study with no FDA obligation attached at all.
The obligations are reporting obligations; the study protocol itself is governed by whatever rules apply to that study type.
What you must do
- 1Report the status of every postmarketing study the applicant committed in writing to conduct, in the same annual report that covers studies FDA required21 CFR 314.81(b)(2)(vii)
- 2Classify each commitment as pending, ongoing, delayed, terminated or submitted using the regulatory definitions, not internal project language21 CFR 314.81(b)(2)(vii)
- 3File that annual report within 60 days of the anniversary date of U.S. approval of the application21 CFR 314.81(b)(2)
- 4For a licensed biologic, submit the equivalent annual progress report against the BLA, including current status, number of patients enrolled and an explanation of any delay21 CFR 601.70
- 5Submit a progress report within one year after approval and annually thereafter until the study is completed or terminated, or state the reasons for the failure to conduct it21 U.S.C. 356b(a)
- 6Keep reporting annually until FDA notifies the applicant in writing that it concurs the study commitment has been fulfilled21 CFR 314.81(b)(2)(vii)
Common mistakes
Leaving a PMC at pending year after year
pending means the study has not started and is not behind schedule. Once the original completion schedule slips, the correct status is delayed, with the explanation attached. An annual report that keeps reporting pending against a schedule that has already passed is inaccurate on its face and is the kind of finding that colors the rest of the filing.
Treating submission of the final study report as closure
submitted is a status, not a discharge. The obligation runs annually until FDA notifies the applicant in writing that it concurs the commitment has been fulfilled, so a team that stops reporting the year it files the study report leaves an open item on the record with nothing tracking it.
Resourcing PMCs as the low-stakes version of PMRs
the mechanics are identical: same annual report, same five status categories, same 60-day deadline off the approval anniversary. Only the enforcement tail differs, and the status still surfaces in the report FDA publishes annually in the Federal Register, so a neglected PMC becomes a public credibility problem before it becomes a regulatory one.
When This Matters
- The approval letter carried one PMR for the pediatric safety study and three PMCs covering drug-drug interaction, renal impairment and long-term immunogenicity.
- Our annual report is due in 40 days and two PMCs are still sitting at pending with no protocol finalized.
- Move that PMC to delayed and write the explanation now; do not let the annual report say ongoing when the schedule has already slipped.
Frequently Asked Questions
A PMC is a study the applicant committed in writing to conduct; a PMR is one FDA required. 21 CFR 314.81(b)(2)(vii) puts both in the same annual status report with the same five status categories, so the operational work is identical. What differs is enforceability: only the required study rests on statutory compulsion.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
Related Regulatory Intelligence
Related Actions
- Lifecycle Management
Track every sequence operation, amendment, and supplement across the product lifecycle.
- Regulatory Intelligence
Monitor FDA, EMA, ICH, and Health Canada guidance changes across active programs.
- Pharma Regulatory Workflows
NDA, BLA, IND, ANDA, and supplement execution in one workspace.
